WHO ICTRP trial
Efficacy and safety of Lenalidomide, PD1 and BTK inhibitor / rituximab in the…
ChiCTR2200056256 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2200056256 |
|---|---|
| Public title | Efficacy and safety of Lenalidomide, PD1 and BTK inhibitor / rituximab in the treatment of relapsed and refractory diffuse Large B-cell lymphoma |
| Scientific title | Efficacy and safety of Lenalidomide, PD1 and BTK inhibitor / rituximab in the treatment of relapsed and refractory diffuse Large B-cell lymphoma |
| Primary sponsor | Yancheng NO1.People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | relapsed and refractory diffuse large B-cell lymphoma |
| Interventions | treatment group:Lenalidomide,PD1 and BTK inhibitor / rituximab |
| Registration date | Feb 3, 2022 |
| Target size | treatment group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: